New biological assay to test viability of cultured cells for in vitro research applications

P. Engbers-Buijtenhuijs, L. Buttafoco, Andreas A. Poot, L.M.Th. Sterk, R.A.I. de Vos, R.H. Geelkerken, Jan Feijen, I. Vermes

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The balance between apoptosis and proliferation of vascular smooth muscle cells (SMCs) is responsible for mediating profound changes in vascular architecture in development and disease. New insights in the biology of SMCs can be important to our understanding of (patho) physiological mechanisms and for tissue-engineering (TE) applications. Here the development of a new method to characterise SMCs regarding proliferation versus apoptosis is described and the application of this method for TE purposes is showed. Proliferation and programmed cell death (apoptosis) of human umbilical vein SMCs were analysed by measuring cyclin E (1) and tissue transglutaminase (tTG) (2) mRNA expression levels with use of a semi-quantitative real-time RT-PCR method. Ratios of cyclin E and tTG were calculated to make a quantified comparison of proliferation versus apoptosis. In this way the viability of SMCs cultured on standard culture systems and on TE scaffolds for small diameter blood vessel constructs were analysed.
Original languageEnglish
Pages (from-to)276-277
JournalNederlands tijdschrift voor klinische chemie en laboratoriumgeneeskunde
Volume29
Issue number5
Publication statusPublished - 2004

Keywords

  • IR-96477
  • METIS-310965

Fingerprint Dive into the research topics of 'New biological assay to test viability of cultured cells for in vitro research applications'. Together they form a unique fingerprint.

  • Cite this

    Engbers-Buijtenhuijs, P., Buttafoco, L., Poot, A. A., Sterk, L. M. T., de Vos, R. A. I., Geelkerken, R. H., ... Vermes, I. (2004). New biological assay to test viability of cultured cells for in vitro research applications. Nederlands tijdschrift voor klinische chemie en laboratoriumgeneeskunde, 29(5), 276-277.